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Background: Fluctuations in blood glucose level cause endothelial dysfunction and play a critical role in onset
and/or progression of atherosclerosis. We hypothesized that fluctuation in blood glucose levels correlate with
vascular endothelial dysfunction and that this relationship can be assessed using common bedside medical devices.
Methods: Fluctuations in blood glucose levels were measured over 24 hours by continuous glucose monitoring
(CGM) on admission day 2 in 57 patients with type 2 diabetes mellitus. The reactive hyperemia index (RHI), an index
of vascular endothelial function, was measured using peripheral arterial tonometry (EndoPAT) on admission day 3.
Results: The natural logarithmic-scaled RHI (L_RHI) correlated with SD (r=−0.504; P<0.001), the mean amplitude of
glycemic excursions (MAGE) (r=−0.571; P<0.001), mean postprandial glucose excursion (MPPGE) (r=−0.411; P=0.001)
and percentage of time ≥200 mg/dl (r=−0.292; P=0.028). In 12 patients with hypoglycemia, L_RHI also correlated
with the percentage of time at hypoglycemia (r=−0.589; P=0.044). L_RHI did not correlate with HbA1c or fasting
plasma glucose levels. Furthermore, L_RHI did not correlate with LDL cholesterol, HDL cholesterol, and triglyceride
levels or with systolic and diastolic blood pressures. Finally, multivariate analysis identified MAGE as the only
significant determinant of L_RHI.
Conclusions: Fluctuations in blood glucose levels play a significant role in vascular endothelial dysfunction in type
2 diabetes.
Trial registration: UMIN000007581
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Death due to ischemic heart disease and onset of
myocardial infarction are approximately 2 to 6 times
greater and the risk of stroke is approximately 2 to 3 times
greater in patients with type 2 diabetes than normal popu-
lation [1-5]. Microvascular complications may be amelio-
rated and/or inhibited by the control of blood glucose
levels through maintenance of hemoglobin A1c (HbA1c)
below a critical level. However, the outcome of recent
large-scale clinical studies suggested that strict glycemic* Correspondence: tanaka@med.uoeh-u.ac.jp
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reproduction in any medium, provided the orcontrol using HbA1c alone is not sufficient to reduce the
risk of macrovascular complications [6,7]; rather, the total
number of deaths remained significantly high after inten-
sive therapy [7]. In this regard, severe hypoglycemia has
been reported to be an important cause of increased inci-
dence of sudden cardiovascular death [8].
In addition to HbA1c, any glucose-lowering therapy tai-
lored to reduce diabetic angiopathy should also improve
postprandial hyperglycemia, which is known to worsen ar-
teriosclerosis, without causing hypoglycemia. In patients
with abnormal glucose tolerance, vascular endothelial
dysfunction is considered one of the main changes in the
initial stage of atherosclerogenesis [9], and is involved in
the onset and progression of macroangiopathy [10].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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strated that accelerated oxidative stress accompanying
fluctuations in blood glucose levels worsens endothelial
dysfunction more than constant hyperglycemia [11], but
there are a few reports that examined the relationship
between fluctuations in blood glucose levels and endo-
thelial dysfunction using instruments commonly avail-
able in clinical practice.
The present study was designed to determine the rela-
tionship between fluctuations in blood glucose levels
and vascular endothelial function using bedside medical
devices in order to identify a suitable index for the pre-
diction of vascular endothelial dysfunction.Methods
A cross-sectional study was conducted involving type 2
diabetic patients who were admitted to the University of
Occupational and Environmental Health, Japan between
April and November 2011 for glycemic control. The
following inclusion criteria were applied in this study:
(1) age, >20 years; (2) blood glucose level at admission of
<300 mg/dl, (3) no diabetic ketosis or non-ketotic hyper-
osmolar coma, and (4) absence of cardiac arrhythmia.
Patients with infectious diseases and/or acute coronary
syndrome were also excluded from the study. The study
protocol was approved by the ethics committees of the
University of Occupational and Environmental Health and
the participating medical centers. Informed consent was
obtained from all subjects.Study design
The study protocol included the use of a continuous
glucose monitoring (CGM) system (CGMSW System
GoldTM, Medtronic Inc., Minneapolis, MN) set at admis-
sion day 0 to measure fluctuations in blood glucose levels
for 72 consecutive hours. Analysis was limited to the data
obtained from the intermediate 48 h of recording to avoid
bias due to insertion and removal of CGM or insufficient
stability of the monitoring system. All patients received
optimal meals (25 kcal/kg of ideal body weight; 60%
carbohydrate, 15–20% protein and 20–25% fat) during
CGM. Peripheral vascular endothelial function assessed by
peripheral vascular arterial tonometry (PAT) provides
non-invasive assessment of vascular health [12], and was
measured by EndoPAT2000 (Itamar Medical, Caesarea,
Israel). PAT allows measurement of reactive hyperemia
index (RHI), a marker of vascular endothelial function,
and involves quantification of arterial pulsatile volume at
rest and during increased shear stress associated with the
release of nitric oxide (NO) [13]. PAT was conducted on
admission day 3.Continuous glucose monitoring system
The mean blood glucose level, standard deviation (SD),
mean amplitude of glycemic excursions (MAGE), mean
postprandial glucose excursion (MPPGE), percentage of
time <70 mg/dl, percentage of time ≥140 mg/dl, and
percentage of time ≥200 mg/dl were measured from the
data recorded through continuous glucose monitoring
(CGM) using self-monitoring blood glucose (SMBG) de-
vice. MAGE, which was proposed by Service et al. [14],
represents fluctuations in blood glucose levels over a 24-
hour period and was calculated from the daily variations
in blood glucose level, which was measured continuously
by CGM over a period of 2 days. To assess postprandial
glucose excursions from CGM data, MPPGE was calcu-
lated as the arithmetic mean of the differences between
the postprandial peak glucose values and the corre-
sponding preprandial glucose values for meals. Previous
studies indicated that interstitial glucose concentrations
measured by CGM correlate with venous blood glucose
levels [15]. CGM measurements represent glucose con-
centrations in the interstitial fluid, but since the intro-
duction of the SMBG technique, the measured value is
considered to represent blood glucose level.
Noninvasive vascular function test
The method used for digital measurement vascular func-
tion using PAT has been described in detail previously
[16]. Based on the circadian variation in peripheral vas-
cular tone, the PAT investigation was performed in
all patients between 7:00 and 8:00 am in a quiet,
temperature-controlled room (21–24°C). All subjects were
examined after an overnight fast and 30-min rest in supine
position. The baseline pulse amplitude was recorded dur-
ing a period of 5 min prior to the induction of ischemia.
The latter was induced by placing the blood pressure cuff
on the upper arm, while the opposite arm served as a con-
trol. The PAT probes were placed on one finger of each
hand. After 5 min, the blood pressure cuff was inflated to
60 mmHg above the systolic pressure or 200 mmHg for
5 min and then deflated to induce reactive hyperemia. As
a measure of reactive hyperemia, RHI was calculated as
the ratio of the average amplitude of the PAT signal over
1 min beginning 1.5 min after cuff deflation (control arm,
A; occluded arm, C) divided by the average amplitude of
the PAT signal over the 2.5-min time period before cuff in-
flation (baseline) (control arm, B; occluded arm, D). Thus,
RHI = (C/D)/(A/B) × baseline correction. Because RHI
has a heteroscedastic error structure, we used a natural
logarithm transformation in all analyses.
Measurement of serum lipids, blood HbA1c, and plasma
glucose
Venous blood samples were taken in the morning fol-
lowing an overnight fast. Serum low-density lipoprotein
Table 1 Patient characteristics
Age (years) 64.8±12.1
Gender (male/female) 32/25
Body mass index (kg/m2) 25.6±4.8
Duration of diabetes (years) 14.0±11.9
Diabetes therapy




α-glucosidase inhibitor 9 (15.8)
dipeptidyl peptidase-4 inhibitor 15 (26.3)
insulin 15 (26.3)
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cholesterol concentrations were measured by standard
enzymatic methods with the use of a kit from Kyowa
Medex (Tokyo, Japan). Triglycerides were measured by
standard enzymatic method (Sekisui Medical Co., Tokyo)
with a fully automated analyzer (JCA-BM6050; JEOL,
Tokyo). The value of HbA1c (%) is estimated as an NGSP
equivalent value (%) derived from the JDS value and calcu-
lated by the formula HbA1c (%) = HbA1c (JDS) (%) +
0.4% [17]. Fasting plasma glucose levels were measured
using a standard enzymatic method. During the study
period, no changes were made to any of the medications
used by the study participants for the control of diabetes,
lipids, and hypertension.Other treatments
Lipid-lowering drugs 32(56.1)
Antihypertensive drugs 31(54.4)
Current smokers 16 (28.1)
Prevalence cardiovascular disease 11 (19.3)
Systolic blood pressure (mmHg) 134.1±20.9






Fasting plasma glucose (mg/dl) 161.3±46.5
Average (mg/dl)a 176.5±47.8
SD (mg/dl) a 42.3±13.2
MAGE (mg/dl) a 110.3±33.4
MPPGE (mg/dl)a 79.9±33.7Statistical analyses
Data were expressed as mean±standard deviation (SD).
The Wilcoxon rank sum test was used for comparison
of groups. Factors that influence natural logarithmic-
scaled RHI (L_RHI) were analyzed using Pearson correl-
ation analysis for normally distributed variables and
Spearman rank correlation for variables with skewed dis-
tribution. Multivariate stepwise regression analysis was
conducted using L_RHI as the dependent variable and
several parameters found to be significantly related to
L_RHI on univariate analysis. The level of significance
was determined as P<0.05. All statistical analyses were
conducted using The Statistical Package for Social
Sciences version 16.0 (SPSS Inc., Chicago, IL, USA). The
association between glucose variability and vascular
function in a sample size of 57 subjects provided power
of 85% at a significance level of 0.05 (r = 0.4).Time at <70 mg/dl (%)a 1.4±3.4
Time at ≥140 mg/dl (%)a 67.2±28.4






Data are mean±SD, n, or n (%). a Measured by the continuous glucose
monitoring system.
Abbreviations: LDL low-density lipoprotein; HDL high-density lipoprotein;
HbA1c hemoglobin A1c; SD standard deviation; MAGE mean amplitude of
glycemic excursion; MPPGE mean postprandial glucose excursions; L_RHI the
natural logarithmic scaled reactive hyperemia index.Results
Clinical characteristics
Patient characteristics are shown in Table 1. The 57
participants were 64.8±12.1 years old (range: 33–
87 years), with a disease duration of 14.0±11.9 years,
fasting plasma glucose level of 161.3±46.5 mg/dl, and
HbA1c of 9.0±1.6% (range: 6.3–15.4%). The study
group included slightly higher number of men, who
were slightly overweight. Forty-eight patients were
treated with oral glucose-lowering agents or insulin.
Eleven (19.3%) patients were diagnosed with various
cardiovascular diseases.
CGM in the 57 patients showed a mean glucose level
of 176.5±47.8 mg/dl (range: 108–321 mg/dl) during the
assessment period. The proportion of time spent in
hypoglycemia during the same period was 1.4±3.4%
(range: 0–16%). The proportion of time spent at glucose
level ≥ 140 mg/dl was 67.2±28.4% (range: 12–100%), and
that at glucose level ≥ 200 mg/dl was 31.4±29.3% (range:0–100%). SD was 42.3±13.2 mg/dl (range: 18–73 mg/dl),
MAGE was 110.3±33.4 mg/dl (range: 37–193 mg/dl),
MPPGE was 79.9±33.7 mg/dl (range: 21.7-192.7 mg/dl),
the mean L_RHI was 0.5±0.2 (men: 0.5, women: 0.5)
(range: 0.1–1.1) and the baseline pulse amplitude was 8.1±3.5
(men: 8.1, women: 8.0) (range: 0.7-15.3).
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control and nonglycemic metabolic variables
Table 2 lists the correlation coefficients of the relation-
ships between L_RHI and markers of diabetic control and
nonglycemic metabolic variables. The univariate analysis
showed that L_RHI was significantly related with SD
(r=−0.504; P<0.001), MAGE (r=−0.571; P<0.001), MPPGE
(r=−0.411; P=0.001) and the percentage of time spent with
glucose ≥200 mg/dl (r=−0.292; P=0.028). The correlation
between L_RHI and percentage of time at hypoglycemia
was significant in 12 hypoglycemic patients (r = −0.589;
P = 0.044) but not in all patients (r = −0.174; P = 0.195).
On the other hand, L_RHI did not correlate with HbA1c
or mean glucose level. Finally, L_RHI did not correlate
with the levels of LDL cholesterol, HDL cholesterol, and
triglycerides, or with systolic and diastolic blood pressures.
Multivariate analysis with L_RHI as the dependent
variable, and age, gender, body mass index (BMI), duration
of the disease, Hypoglycemic agents, Antihypertensive
drugs, Lipid-lowering drugs, Prevalence cardiovascular
disease, LDL cholesterol, HDL cholesterol, triglycerides,
systolic blood pressure, SD, MAGE, the percentage of time
with blood glucose <70 mg/dl, and the percentage of time
with blood glucose ≥200 mg/dl as the independent vari-
ables, identified MAGE (Adjusted multiple R2=0.314,
Standardized coefficient β=−0.571, t=−5.162, P<0.001) as
the only independent and significant determinants of
L_RHI (Table 3).Table 2 Correlation coefficients between L_RHI and markers o
variables
HbA1c Averagea SDa MAGEa M
Averagea (n=57) 0.14
SDa (n=57) −0.16 0.36**
MAGEa (n=57) −0.06 0.30* 0.79**
MMPGEa (n=57) 0.01 0.37** 0.64** 0.58**
Time at <70a with hypoglycemia
(n=12)
0.29 −0.69** −0.38 −0.70* −
Time at ≥140a (n=57) 0.12 0.84** 0.27* 0.18
Time at ≥200a (n=57) 0.14 0.95** 0.43** 0.37**
LDL-C (n=57) 0.26 −0.01 −0.23 −0.13
HDL-C (n=57) −0.17 0.01 0.31* 0.04
TG (n=57) 0.27* 0.05 −0.21 −0.03
SBP (n=57) −0.07 −0.25 −0.09 0.01 −
DBP (n=57) 0.20 −0.20 −0.27* −0.12 −
L_RHI (n=57) 0.12 −0.24 −0.50** −0.57** −
a Measured by the continuous glucose monitoring system.
Data are results of Pearson correlation analysis for normally distributed variables an
**P<0.01.
Abbreviations: HbA1c hemoglobin A1c; SD standard deviation; MAGE, mean amplitu
LDL-C low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholestero
L_RHI the natural logarithmic scaled reactive hyperemia index.Rubinshtein et al. [18] reported that cardiovascular
events were significantly higher in patients with L_RHI
values of <0.4. Accordingly, we divided the patients into
two groups, the low L_RHI group (L_RHI <0.4, n=16) and
the high L_RHI group (L_RHI ≥0.4, n=41), and investi-
gated glucose fluctuations in the two groups. MAGE was
103.2±30.5 mg/dl in the high L_RHI group, and signifi-
cantly lower than in the low L_RHI group (128.8±34.4 mg/
dl, P=0.014). Furthermore, the mean glucose level was
187.6±48.4 mg/dl in the low L_RHI group and 172.2
±47.5 mg/dl in the high L_RHI group, but these two values
were not significantly different (P=0.143).
Discussion
Previous studies reported that RHI correlates with vas-
cular endothelial dysfunction and is a risk factor for the
onset of cardiovascular events [12,19,20]. Based on this
background, we used RHI as an index of vascular endo-
thelial dysfunction. This study clarifies the relationship
between vascular endothelial function and glucose me-
tabolism, in particular, fluctuations in blood glucose
levels.
While there was no relationship between L_RHI and
indexes of mean hyperglycemia such as HbA1c and/or
mean blood glucose level, vascular endothelial dysfunc-
tion correlated with SD, MAGE, MPPGE and the per-
centage of time spent with glucose ≥200 mg/dl, a
measure of fluctuation of blood glucose level and knownf diabetic control and various nonglycemic metabolic











0.04 0.65* −0.10 −0.04
0.19 0.03 0.17 0.05 0.06
0.06 −0.33 0.04 0.01 0.16 −0.28*
0.03 −0.07 −0.19 −0.22 −0.07 −0.18 0.05
0.10 −0.07 −0.16 −0.22 0.09 −0.26* 0.17 0.65**
0.41** −0.59* −0.20 −0.29* 0.17 −0.14 0.01 0.11 0.09
d Spearman rank correlation for variables with skewed distribution. *P<0.05,
de of glycemic excursions; MPPGE mean postprandial glucose excursions;
l; TG triglyceride; SBP systolic blood pressure; DBP diastolic blood pressure;
Table 3 Linear multivariate analyses with L_RHI as the dependent variable.




Intercept 0.923 0.083 11.088 <0.001
MAGE −0.004 0.001 −0.571 −5.162 <0.001
Adjusted Multiple R2 0.314
Multivariate stepwise regression analysis with L_RHI as the dependent variable and age, gender, BMI, duration of the disease, Hypoglycemic agents,
Antihypertensive drugs, Lipid-lowering drugs, Prevalence cardiovascular disease, LDL-cholesterol, HDL-cholesterol, triglyceride, systolic blood pressure, HbA1c, SD,
MAGE, Time at blood glucose <70 mg/dl and Time at blood glucose ≥200 mg/dl as the independent variables.
MAGE, Time at blood glucose <70 mg/dl and Time at blood glucose ≥200 mg/dl were measured by the continuous glucose monitoring system.
Abbreviations: SE Standard error; LDL low-density lipoprotein; HDL high-density lipoprotein; HbA1c hemoglobin A1c; SD standard deviation; MAGE mean amplitude
of glycemic excursions; L_RHI the natural logarithmic scaled reactive hyperemia index.
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percentage of time at hypoglycemia. Furthermore, multi-
variate analysis identified MAGE as the only determin-
ant of vascular endothelial dysfunction in this study.
Vascular endothelial dysfunction occurs in the early
stage of atherosclerogenesis and is involved in the pro-
gression of atherosclerosis [9]. Buscemi et al. [21]
reported that glycemic variability influenced endothelial
function even in non-diabetic subjects. Monnier et al.
[22] indicated that large fluctuations in postprandial
blood glucose levels measured by CGM increased oxida-
tive stress more than high blood glucose levels with
HbA1c as an index. Using the glucose clamp method,
Ceriello et al. [11] reported that worsening of oxidative
stress in association with blood glucose fluctuations
resulted in endothelial deterioration and dysfunction
that exceeded the harmful effects of constantly high
blood glucose levels. Recently, Rizzo et al. [23] reported
that MAGE reduction is associated with reduction of
oxidative stress and markers of systemic inflammation
by treatment of dipeptidyl peptidase-IV inhibitor in type
2 diabetic patients. Monnier et al. [24] reported that any
strategy should target markers of glycemic variability
such as MAGE to limit the risk of complications. The
present study examined the relationship between blood
glucose fluctuations and endothelial dysfunction using
instruments commonly available in clinical practice, i.e.,
CGM and PAT.
In cases with normal glucose tolerance, vascular endo-
thelial function correlates with postprandial glucose fluc-
tuation, insulin resistance, and postprandial serum insulin
level [25], and within the normoglycemic range, indivi-
duals whose 2-h plasma glucose levels did not return to
their fasting plasma glucose levels during OGTT had ele-
vated fasting insulin levels and increased incidence of cor-
onary heart disease [26]. Patients with mild abnormalities
in glucose metabolism are reported to suffer from endo-
thelial dysfunction. Transient hyperglycemia induces
oxidative stress [27], the release of proinflammatory cyto-
kines [28], increases reactive oxygen species (ROS) [29],
and reduces NO production in association with increased
levels of asymmetric dimethylarginine (ADMA) [30].These reactions are mediated through the translocation
and activation of nuclear factor-κB (NF-κB) and the pro-
ducts are thought to be involved in vascular endothelial
dysfunction. Su et al. [31] reported that glucose excursion
and hs-CRP are associated with the presence and severity
of CAD and that glycemic variability measured by CGM
correlates with interleukin-6 (IL-6) concentration [32].
The present study also demonstrated that vascular endo-
thelial dysfunction also correlated with MPPGE and the
time spent at blood glucose level of ≥200 mg/dl, in
addition to postprandial hyperglycemia. In agreement with
Di Flaviani et al. [33], established postprandial hypergly-
cemia is a detrimental factor in reduced flow-mediated
vasodilation and activation of oxidative stress is associated
with increased glucose variability in type 2 diabetes. In
contrast, Peña et al. [34] reported that glucose variability,
as measured by CGM, is not associated with vascular
function in type 1 diabetes. This highlights possible differ-
ences in the role of glucose variability in arteriosclerosis in
type 1 and type 2 diabetes.
Although the sample size was very small, the results of
the present study highlighted the role of hypoglycemia in
vascular endothelial dysfunction. There was no significant
difference in the reduction of risk for macrovascular com-
plications between the standard treatment and consolida-
tion treatment groups in the ACCORD study; rather, the
total number of deaths was significantly higher [7], and
the number of sudden cardiovascular deaths was also
higher [8] in patients with severe hypoglycemia. What are
the underlying mechanisms of the poor outcome in
patients with hypoglycemia? While the present study did
not investigate this important question, others have
reported the potential roles of sympathetic nerve activa-
tion, proinflammatory cytokine secretion, and activation
of coagulation factors in hypoglycemic-induced cardiovas-
cular events [35].
In a large community-based cohort, the factors asso-
ciated with L_RHI were male sex, diabetes mellitus, use of
anti-hypertension drugs and the ratio of total cholesterol
to HDL cholesterol [36]. However, in that study, L_RHI
values did not correlate with male sex, hypertension drugs
or markers of cholesterol metabolism. The difference in
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specific determinants of endothelial function or, alterna-
tively, to the presence of higher baseline pulse amplitude
in men compared to women [36]. In the present study,
there was no difference in baseline pulse amplitude be-
tween males and females, which may explain why there
was no difference in L_RHI values.
The present study has certain limitations. First, the
subjects were patients admitted to the hospital. The
mean blood glucose level measured by CGM was
176.5 mg/dl (9.8 mmol/l). However, the mean HbA1c of
the patients was 9.0%; thus, the calculated mean blood
glucose level corresponding to this HbA1c value is
234.6 mg/dl (13.0 mmol/l) [37]. This discrepancy was
possibly related to the strict diet provided during
hospitalization. Second, the results showed no correl-
ation between L_RHI and a marker of fasting cholesterol
metabolism. This finding was probably related to the
small sample size and treatment of approximately half of
the patients with statin. Third, this study was cross-sec-
tional, which precluded evaluation of the cause–effect re-
lationship between glycemic variability and vascular
function. Fourth, we could not assess the relationship be-
tween oxidative stress or inflammation and PAT. Fifth,
the sample size in the present study was relatively small;
therefore, subgroup comparisons may lack statistical
power. Finally, because the number of subjects in the
present study was small, our results should be verified in
another study that includes a larger number of subjects.
Conclusions
In conclusion, the present study demonstrated that
vascular endothelial function is influenced by fluctuations
in blood glucose levels and acute hyperglycemia of
>200 mg/dl. Further well-designed studies of patients with
type 2 diabetes are necessary to investigate the long-term
effects of fluctuations in blood glucose levels on endothe-
lial function and the possible contribution of such dys-
function on the development of diabetic angiopathies.
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